LENSAR (LENSAR) Days Sales Outstanding : 29.58 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is LENSAR Days Sales Outstanding?

LENSAR's average Accounts Receivable for the three months ended in Dec. 2023 was $3.92 Mil. LENSAR's Revenue for the three months ended in Dec. 2023 was $12.11 Mil. Hence, LENSAR's Days Sales Outstanding for the three months ended in Dec. 2023 was 29.58.

The historical rank and industry rank for LENSAR's Days Sales Outstanding or its related term are showing as below:

LNSR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.22 Med: 40.46 Max: 55.11
Current: 37.69

During the past 5 years, LENSAR's highest Days Sales Outstanding was 55.11. The lowest was 35.22. And the median was 40.46.

LNSR's Days Sales Outstanding is ranked better than
86.63% of 808 companies
in the Medical Devices & Instruments industry
Industry Median: 64.725 vs LNSR: 37.69

LENSAR's Days Sales Outstanding declined from Dec. 2022 (42.81) to Dec. 2023 (29.58).

LENSAR Days Sales Outstanding Historical Data

The historical data trend for LENSAR's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR Days Sales Outstanding Chart

LENSAR Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

40.46

37.33

35.22

55.11

43.46

LENSAR Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial													42.81	59.16	29.94	32.94	29.58

Competitive Comparison of LENSAR's Days Sales Outstanding

For the Medical Devices subindustry, LENSAR's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENSAR's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where LENSAR's Days Sales Outstanding falls into.

LENSAR Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

LENSAR's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (6.04	+	4.001)	/	2 )	/	42.164	*	365
=	5.0205					/	42.164	*	365
=	43.46

LENSAR's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (3.848	+	4.001)	/	2 )	/	12.105	*	365 / 4
=	3.9245					/	12.105	*	365 / 4
=	29.58

LENSAR (NAS:LNSR) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

LENSAR Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of LENSAR's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

LENSAR (LENSAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

2800 Discovery Drive, Orlando, FL, USA, 32826

Website

https://www.lensar.com

LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer	director, 10 percent owner	NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis	director, 10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc	10 percent owner	62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii	officer: Chief Financial Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong	officer: Principal Accounting Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton	officer: Chief Operating Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis	director, officer: Chief Executive Officer	C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc.	10 percent owner	59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391